186 related articles for article (PubMed ID: 32778990)
41. A somatic splice-site variant in PIK3R1 in a patient with vascular overgrowth and low immunoglobulin levels: A case report.
Wilke MVMB; Schimmenti L; Lopour MQR; Tollefson MM; Klee EW
Mol Genet Genomic Med; 2023 Dec; 11(12):e2271. PubMed ID: 37641480
[TBL] [Abstract][Full Text] [Related]
42. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
43. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
44. Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.
Moreno-Corona N; Chentout L; Poggi L; Thouenon R; Masson C; Parisot M; Mouel LL; Picard C; André I; Cavazzana M; Perrin L; Durandy A; Azarnoush S; Kracker S
Front Pediatr; 2021; 9():688022. PubMed ID: 34249818
[TBL] [Abstract][Full Text] [Related]
45. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
46. Case Report: Hodgkin Lymphoma and Refractory Systemic Lupus Erythematosus Unveil Activated Phosphoinositide 3-Kinase-δ Syndrome 2 in an Adult Patient.
Conti F; Catelli A; Cifaldi C; Leonardi L; Mulè R; Fusconi M; Stefoni V; Chiriaco M; Rivalta B; Di Cesare S; Schifino G; Sbrega F; Di Matteo G; Ferrari S; Cancrini C; Pession A
Front Pediatr; 2021; 9():702546. PubMed ID: 34307262
[No Abstract] [Full Text] [Related]
47. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
48. [Clinical and immunological characteristics of a case with activated phosphoinositide 3-kinase δ syndrome 2].
Yang QY; Jia YJ; Wang YP; Zeng T; Zhao XD; Zhou LN
Zhonghua Er Ke Za Zhi; 2020 May; 58(5):413-417. PubMed ID: 32392959
[No Abstract] [Full Text] [Related]
49. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases.
Dornan GL; Burke JE
Front Immunol; 2018; 9():575. PubMed ID: 29616047
[TBL] [Abstract][Full Text] [Related]
50. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
51. Extrahematopoietic manifestations of the short telomere syndromes.
Schratz KE
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):115-122. PubMed ID: 33275732
[TBL] [Abstract][Full Text] [Related]
52. Case Report: Activating
Lu M; Gu W; Sheng Y; Wang J; Xu X
Front Immunol; 2021; 12():670312. PubMed ID: 33995405
[TBL] [Abstract][Full Text] [Related]
53. Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants.
Hargreaves CE; Dhalla F; Patel AM; de Oteyza ACG; Bateman E; Miller J; Anzilotti C; Ayers L; Grimbacher B; Patel SY
Clin Immunol; 2022 Jan; 234():108910. PubMed ID: 34922003
[TBL] [Abstract][Full Text] [Related]
54. Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome.
Thauland TJ; Pellerin L; Ohgami RS; Bacchetta R; Butte MJ
Front Immunol; 2019; 10():753. PubMed ID: 31031754
[TBL] [Abstract][Full Text] [Related]
55. SHORT Syndrome: Systematic Appraisal of the Medical and Dental Phenotype.
Mubeen S; Gibson C; Mubeen R; Mansour S; Evans RD
Cleft Palate Craniofac J; 2022 Jul; 59(7):873-881. PubMed ID: 34212753
[TBL] [Abstract][Full Text] [Related]
56. Generation, establishment and characterization of a pluripotent stem cell line (CVTTHi001-A) from primary fibroblasts isolated from a patient with activated PI3 kinase delta syndrome (APDS2).
Inglés-Ferrándiz M; Martin-Inaraja M; Herrera L; Villaverde M; Santos S; Vesga MA; Garreta E; Martín-Ruiz I; Aransay AM; Anguita J; Barreña B; Allende LM; Gonzalez-Granado LI; Eguizabal C
Stem Cell Res; 2020 Dec; 49():102082. PubMed ID: 33221676
[TBL] [Abstract][Full Text] [Related]
57. Short syndrome-an expanding phenotype.
Singh A; Arora R; Singh P; Kapoor S
Indian Pediatr; 2013 Apr; 50(4):414-6. PubMed ID: 23665600
[TBL] [Abstract][Full Text] [Related]
58. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.
Reardon W; Temple IK
Am J Med Genet A; 2008 May; 146A(10):1296-8. PubMed ID: 18384141
[TBL] [Abstract][Full Text] [Related]
59. Infections in activated PI3K delta syndrome (APDS).
Brodsky NN; Lucas CL
Curr Opin Immunol; 2021 Oct; 72():146-157. PubMed ID: 34052541
[TBL] [Abstract][Full Text] [Related]
60. [A case of PIK3R1 gene variation induced SHORT syndrome].
Cao BY; Wu D; Gong CX
Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):228-230. PubMed ID: 33657699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
